TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Radiopharm Theranostics Limited ( (AU:RAD) ) has provided an announcement.
Radiopharm Theranostics Limited announced that all resolutions at their Annual General Meeting were passed by poll, with significant support for key resolutions. The meeting confirmed the re-appointment of Mr. Bruce Goodwin as a Non-Executive Director, indicating stability in the company’s governance. The approval of various resolutions, including the issuance of equity securities and incentive options, suggests strategic moves to strengthen the company’s operational capabilities and align management incentives with shareholder interests.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the medical technology industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company aims to enhance the precision and effectiveness of cancer treatment through its innovative theranostic solutions.
Average Trading Volume: 6,617,441
Technical Sentiment Signal: Sell
Current Market Cap: A$63.96M
See more data about RAD stock on TipRanks’ Stock Analysis page.